Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Zoledronic Acid in Advanced HCC
NCT01259193Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Oct 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in hepatocellular carcinoma (HCC), sponsored by Fudan University. Primary endpoint: Numbers of Adverse Events at 1 year. Status: unknown.
02
Drugs
zoledronic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01259193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01259193.